Table 1.
Conscious echocardiographic analysis of Acsl1H−/− hearts 10 weeks after tamoxifen (or control) induction.
| Control n=4 |
Acsl1H−/− n=8 |
Control n=5 |
Acsl1H−/− n=9 |
|
|---|---|---|---|---|
| Vehicle | Rapamycin | |||
| Heart Rate (bpm) | 660.0 ± 33.8 | 650.1 ± 18.2 | 675.8 ± 28.9 | 686.1 ± 22.7 |
| IVS,d (mm) | 1.13 ± 0.05 | 1.32 ± 0.08* | 1.00 ± 0.05 | 1.11 ± 0.05 |
| LVID,d (mm) | 2.69 ± 0.13 | 2.70 ± 0.13 | 2.83 ± 0.11 | 2.60 ± 0.06 |
| LVPW,d (mm) | 1.04 ± 0.05 | 1.18 ± 0.06* | 0.94 ± 0.05 | 1.04 ± 0.05 |
| IVS,s (mm) | 1.71 ± 0.07 | 1.94 ± 0.06* | 1.62 ± 0.13 | 1.70 ± 0.05 |
| LVID,s (mm) | 1.37 ± 0.15 | 1.27 ± 0.11 | 1.32 ± 0.12 | 1.16 ± 0.07 |
| LVPW,s (mm) | 1.50 ± 0.06 | 1.85 ± 0.07* | 1.50 ± 0.09 | 1.56 ± 0.04 |
| LV Vol;d (μl) | 27.1 ± 3.4 | 27.8 ± 3.2 | 30.6 ± 2.7 | 24.9 ± 1.4 |
| LV Vol;s (μl) | 5.2 ± 1.4 | 4.4 ± 1.0 | 4.6 ±1.1 | 3.3 ± 0.5 |
| FS (%) | 49.1 ± 4.4 | 53.1 ± 2.9 | 53.6 ± 3.0 | 55.4 ± 1.7 |
| EF (%) | 81.4 ± 4.0 | 84.8 ± 2.6 | 85.4 ± 2.8 | 87.2 ± 1.3 |
| LV Mass (mg) | 99.9 ± 0.8 | 128.3 ± 7.5* | 90.6 ± 5.9 | 95.2 ± 6.2 |
Differences between treatment groups were evaluated by one-way ANOVA, followed by an all pairwise Holm-Sidak multiple comparison procedure; *p<≤0.05 versus all other groups.
IVS, interventricular septum; LVID, left ventricular inner diameter; LVPW, left ventricular posterior wall; LV Vol, left ventricular volume; % EF, ejection fraction; fractional shortening; LV, left ventricular; d, diastole; s, systole. Data represent mean ± SEM;
*
p<0.05.